Estrogens, conjugated
Amnestrogen, Duavee, Estratab, Evex, Femogen, Menrium, Milprem, Pmb, Premarin, Premphase, Prempro (estrogens, conjugated) is a small molecule pharmaceutical. Estrogens, conjugated was first approved as Menrium 5-2 on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Premarin (generic drugs available since 1982-01-01, discontinued: Amnestrogen, Estratab, Evex, Femogen)
CombinationsDuavee, Premphase, Prempro (discontinued: Menrium, Milprem, Pmb, Premphase (premarin;cycrin ), Prempro (premarin;cycrin))
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bazedoxifene acetate
+
Estrogens
+
conjugated
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUAVEE | WYETH PHARMS | N-022247 RX | 2013-10-03 | 1 products, RLD, RS |
Chlordiazepoxide
+
Estrogens
+
esterified
Estrogens
+
conjugated
Estrogens
+
conjugated
+
Medroxyprogesterone acetate
Estrogens
+
conjugated
+
Meprobamate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| duavee | New Drug Application | 2022-12-20 |
| menest | ANDA | 2020-11-20 |
| premarin | New Drug Application | 2022-11-28 |
| premphase prempro | New Drug Application | 2019-12-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
210 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 6 | 9 | 2 | 10 | 6 | 33 |
| Postmenopause | D017698 | 8 | 6 | 8 | 1 | 3 | 26 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 4 | 4 | 1 | 3 | 14 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 9 | 1 | 2 | 13 |
| Hot flashes | D019584 | — | 1 | 3 | 2 | 2 | 8 | ||
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | 1 | 3 | 2 | 6 | |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | 1 | 1 | 4 | 1 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 1 | 3 | 5 |
| Infertility | D007246 | EFO_0000545 | 1 | 1 | 1 | 2 | 1 | 5 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 3 | 2 | 5 |
Show 33 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 10 | — | 2 | 13 |
| Coronary disease | D003327 | — | 1 | 10 | — | 2 | 12 | ||
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | 8 | — | 2 | 11 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 7 | — | 1 | 8 |
| Healthy volunteers/patients | — | 4 | 1 | 1 | — | — | 5 | ||
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | — | 1 | — | 2 | 4 |
| Coronary artery disease | D003324 | I25.1 | — | 1 | 4 | — | — | 4 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | 2 | — | — | 4 |
| Prostatic neoplasms | D011471 | C61 | — | 1 | 1 | — | 1 | 3 | |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 3 | 2 | — | — | 3 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 2 | — | — | — | 2 |
| Risk reduction behavior | D040242 | — | 1 | — | — | — | 1 | ||
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | 1 | — | — | — | 1 | ||
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Prehypertension | D058246 | — | 1 | — | — | — | 1 | ||
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen replacement therapy | D015914 | 2 | — | — | — | 1 | 3 | ||
| Memory | D008568 | 1 | — | — | — | — | 1 | ||
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | 1 | — | — | — | — | 1 | |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | 1 | — | — | — | — | 1 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 2 | 2 |
| Hypogonadism | D007006 | E23.0 | — | — | — | — | 2 | 2 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 2 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Postoperative pain | D010149 | G89.18 | — | — | — | — | 1 | 1 | |
| Pregnancy outcome | D011256 | — | — | — | — | 1 | 1 | ||
| Heart disease risk factors | D000082742 | — | — | — | — | 1 | 1 | ||
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Breast feeding | D001942 | — | — | — | — | 1 | 1 | ||
| Neurologic manifestations | D009461 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESTROGENS, CONJUGATED |
| INN | — |
| Description | Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle.
|
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 12126-59-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201649 |
| ChEBI ID | — |
| PubChem CID | 656613 |
| DrugBank | DB00286 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Premarin - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,925 documents
View more details
Safety
Black-box Warning
Black-box warning for: Duavee, Menest, Premarin, Premphase prempro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
689 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more